BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16094421)

  • 1. Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside.
    Bruno B; Giaccone L; Rotta M; Anderson K; Boccadoro M
    Leukemia; 2005 Oct; 19(10):1729-38. PubMed ID: 16094421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
    Anderson KC
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):155-62. PubMed ID: 17379101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New horizons in multiple myeloma therapy.
    Santos ES; Kharfan-Dabaja MA
    Expert Rev Anticancer Ther; 2006 Oct; 6(10):1483-501. PubMed ID: 17069532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards a new age in the treatment of multiple myeloma.
    Piazza FA; Gurrieri C; Trentin L; Semenzato G
    Ann Hematol; 2007 Mar; 86(3):159-72. PubMed ID: 17205287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapsed/Refractory multiple myeloma: defining refractory disease and identifying strategies to overcome resistance.
    Siegel DS
    Semin Hematol; 2012 Jul; 49 Suppl 1():S3-15. PubMed ID: 22727390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New drugs for treatment of multiple myeloma.
    Bruno B; Rotta M; Giaccone L; Massaia M; Bertola A; Palumbo A; Boccadoro M
    Lancet Oncol; 2004 Jul; 5(7):430-42. PubMed ID: 15231250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.
    Podar K; Richardson PG; Chauhan D; Anderson KC
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):551-66. PubMed ID: 17428175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics, pathogenesis, and novel treatments for multiple myeloma.
    San Miguel J
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S1-4. PubMed ID: 19791422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging pathways as individualized therapeutic target of multiple myeloma.
    Misso G; Zappavigna S; Castellano M; De Rosa G; Di Martino MT; Tagliaferri P; Tassone P; Caraglia M
    Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S95-109. PubMed ID: 23738692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging drugs in multiple myeloma.
    Ghobrial IM; Leleu X; Hatjiharissi E; Hideshima T; Mitsiades C; Schlossman R; Anderson KC; Richardson P
    Expert Opin Emerg Drugs; 2007 Mar; 12(1):155-63. PubMed ID: 17355220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding novel therapeutic agents for multiple myeloma.
    Tariman JD
    Clin J Oncol Nurs; 2003; 7(5):521-8. PubMed ID: 14603548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches.
    Kizaki M; Tabayashi T
    J Clin Exp Hematop; 2016; 56(1):20-7. PubMed ID: 27334854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model.
    Kharaziha P; De Raeve H; Fristedt C; Li Q; Gruber A; Johnsson P; Kokaraki G; Panzar M; Laane E; Osterborg A; Zhivotovsky B; Jernberg-Wiklund H; Grandér D; Celsing F; Björkholm M; Vanderkerken K; Panaretakis T
    Cancer Res; 2012 Oct; 72(20):5348-62. PubMed ID: 22952216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
    Bladé J; Cibeira MT; Rosiñol L
    Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanisms of novel therapeutic approaches for multiple myeloma.
    Hideshima T; Anderson KC
    Nat Rev Cancer; 2002 Dec; 2(12):927-37. PubMed ID: 12459731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New drugs for myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
    Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of new drugs for the treatment of patients with multiple myeloma.
    Kenealy M; Prince HM
    Intern Med J; 2006 Dec; 36(12):781-9. PubMed ID: 17096741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies.
    Moreau P
    Semin Hematol; 2012 Jul; 49 Suppl 1():S33-46. PubMed ID: 22727391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug insight: thalidomide as a treatment for multiple myeloma.
    Kumar S; Anderson KC
    Nat Clin Pract Oncol; 2005 May; 2(5):262-70. PubMed ID: 16264962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic approaches to myeloma bone disease: an evolving story.
    Longo V; Brunetti O; D'Oronzo S; Dammacco F; Silvestris F
    Cancer Treat Rev; 2012 Oct; 38(6):787-97. PubMed ID: 22494965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.